survey, developmental biology, immunology
Zika and Dengue Immunity: A Complex Relationship
Zika and Dengue Immunity: A Complex Relationship
Amanda B. Keener | Jun 28, 2016
Researchers examine the blood of people infected with dengue virus, finding a few Zika-neutralizing antibodies among mostly enhancing ones.
Sex Differences in Immune Response
Sex Differences in Immune Response
Tanya Lewis | Jun 21, 2016
Female mice lacking an immune receptor are better than males at fighting certain viral infections.
Plastic Pollutants Can Harm Fish
Plastic Pollutants Can Harm Fish
Tracy Vence | Jun 6, 2016
European perch larvae exposed to environmentally relevant concentrations of polystyrene particles preferred to eat the microplastics in place of prey, according to a study.
Thirumala-Devi Kanneganti: Immersed in Immunology
Thirumala-Devi Kanneganti: Immersed in Immunology
Karen Zusi | Jun 1, 2016
Member, Department of Immunology, St. Jude Children’s Research Hospital. Age: 43
Enhancing Vaccine Development
Enhancing Vaccine Development
Wudan Yan | Jun 1, 2016
Using proteomics methods to inform antigen selection
Research at Micro- and Nanoscales
Research at Micro- and Nanoscales
Mary Beth Aberlin | Jun 1, 2016
From whole cells to genes, closer examination continues to surprise.
 
Contributors
Contributors
Catherine Offord | Jun 1, 2016
Meet some of the people featured in the June 2016 issue of The Scientist.
Toward Targeted Therapies for Autoimmune Disorders
Toward Targeted Therapies for Autoimmune Disorders
Lawrence Steinman | Jun 1, 2016
Training the immune system to cease fire on native tissues could improve outcomes for autoimmune patients, but clinical progress has been slow.
Editing Genomes to Record Cellular Histories
Editing Genomes to Record Cellular Histories
Ruth Williams | May 26, 2016
Researchers harness the power of genome editing to track cell lineages throughout zebrafish development.
FDA Approves Bladder Cancer Immunotherapy
FDA Approves Bladder Cancer Immunotherapy
Jef Akst | May 23, 2016
The US Food and Drug Administration greenlights Roche’s Tecentriq, which blocks a protein that obstructs the immune system’s ability to fight cancer.